Could a simple hormone shot improve IVF live birth rates?

NCT ID NCT04064840

First seen May 15, 2026 · Last updated Jun 20, 2026 · Updated 6 times

Summary

This study tests whether adding a hormone drug called Decapeptyl to standard IVF treatments can increase the number of live births. About 784 women under 43 with subfertility will receive either the drug or a placebo during egg retrieval and embryo transfer. The goal is to see if this approach leads to more successful pregnancies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUBFERTILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Obstetrics and Gynaecology

    RECRUITING

    Hong Kong, Hong Kong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Decapeptyl (gonadotropin-releasing hormone agonist)

What this could lead to

If successful, this could offer a simple drug adjustment to improve the chance of a live birth in IVF and frozen embryo transfers.

What could go wrong

This is a single-center trial, and results may not apply to all fertility clinics or patient groups. The drug may cause side effects like ovarian hyperstimulation or hormone imbalances.

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.